- Home
- XPO vs ILMN Comparison
XPO vs ILMN Comparison
Compare XPO & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XPO
- ILMN
- Stock Information
- Founded
- XPO 2000
- ILMN 1998
- Country
- XPO United States
- ILMN United States
- Employees
- XPO N/A
- ILMN N/A
- Industry
- XPO Transportation Services
- ILMN Medical Specialities
- Sector
- XPO Consumer Discretionary
- ILMN Health Care
- Exchange
- XPO Nasdaq
- ILMN Nasdaq
- Market Cap
- XPO 16.0B
- ILMN 18.4B
- IPO Year
- XPO N/A
- ILMN 2000
- Fundamental
- Price
- XPO $134.08
- ILMN $121.34
- Analyst Decision
- XPO Strong Buy
- ILMN Hold
- Analyst Count
- XPO 18
- ILMN 15
- Target Price
- XPO $145.61
- ILMN $114.93
- AVG Volume (30 Days)
- XPO 1.4M
- ILMN 2.0M
- Earning Date
- XPO 10-30-2025
- ILMN 10-30-2025
- Dividend Yield
- XPO N/A
- ILMN N/A
- EPS Growth
- XPO N/A
- ILMN N/A
- EPS
- XPO 2.78
- ILMN 4.46
- Revenue
- XPO $8,068,000,000.00
- ILMN $4,288,000,000.00
- Revenue This Year
- XPO $1.30
- ILMN N/A
- Revenue Next Year
- XPO $3.90
- ILMN $2.22
- P/E Ratio
- XPO $48.11
- ILMN $27.05
- Revenue Growth
- XPO N/A
- ILMN N/A
- 52 Week Low
- XPO $85.06
- ILMN $68.70
- 52 Week High
- XPO $161.00
- ILMN $153.06
- Technical
- Relative Strength Index (RSI)
- XPO 49.41
- ILMN 64.31
- Support Level
- XPO $136.38
- ILMN $118.50
- Resistance Level
- XPO $142.03
- ILMN $125.50
- Average True Range (ATR)
- XPO 5.68
- ILMN 5.35
- MACD
- XPO -0.08
- ILMN 0.77
- Stochastic Oscillator
- XPO 54.69
- ILMN 84.19
About XPO XPO Inc.
Following the spinoff of its contract logistics division (GXO) in 2021 and freight brokerage operations (RXO) in 2022, XPO is moving closer to becoming a pure-play asset-based less-than-truckload carrier. We estimate LTL shipping makes up 60% of total revenue, with XPO's European truckload and LTL operations making up 40%. However, XPO's LTL segment EBITDA mix is much higher than 60%. We believe XPO intends to divest its European trucking division once it finds the right buyer.
About ILMN Illumina Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.